751 related articles for article (PubMed ID: 17333344)
41. New Antifolates: Pharmacology and Clinical Applications.
Takimoto CH
Oncologist; 1996; 1(1 & 2):68-81. PubMed ID: 10387971
[TBL] [Abstract][Full Text] [Related]
42. Impaired CREB-1 phosphorylation in antifolate-resistant cell lines with down-regulation of the reduced folate carrier gene.
Rothem L; Stark M; Assaraf YG
Mol Pharmacol; 2004 Dec; 66(6):1536-43. PubMed ID: 15340044
[TBL] [Abstract][Full Text] [Related]
43. Drug resistance in colon cancer.
Gorlick R; Bertino JR
Semin Oncol; 1999 Dec; 26(6):606-11. PubMed ID: 10606253
[TBL] [Abstract][Full Text] [Related]
44. Mechanism-based inhibitors of folylpoly-gamma-glutamate synthetase and gamma-glutamyl hydrolase: control of folylpoly-gamma-glutamate homeostasis as a drug target.
Coward JK; McGuire JJ
Vitam Horm; 2008; 79():347-73. PubMed ID: 18804701
[TBL] [Abstract][Full Text] [Related]
45. Design and rationale for novel antifolates.
Bertino JR; Sobrero A; Mini E; Moroson BA; Cashmore A
NCI Monogr; 1987; (5):87-91. PubMed ID: 3431593
[TBL] [Abstract][Full Text] [Related]
46. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
Peters GJ; Smitskamp-Wilms E; Smid K; Pinedo HM; Jansen G
Cancer Res; 1999 Nov; 59(21):5529-35. PubMed ID: 10554030
[TBL] [Abstract][Full Text] [Related]
47. Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma.
Mairinger F; Vollbrecht C; Halbwedl I; Hatz M; Stacher E; Gülly C; Quehenberger F; Stephan-Falkenau S; Kollmeier J; Roth A; Mairinger T; Popper H
J Thorac Oncol; 2013 May; 8(5):644-53. PubMed ID: 23449276
[TBL] [Abstract][Full Text] [Related]
48. Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: part I.
Gangjee A; Jain HD; Kurup S
Anticancer Agents Med Chem; 2007 Sep; 7(5):524-42. PubMed ID: 17896913
[TBL] [Abstract][Full Text] [Related]
49. Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates.
Bram E; Ifergan I; Shafran A; Berman B; Jansen G; Assaraf YG
Cancer Chemother Pharmacol; 2006 Dec; 58(6):826-34. PubMed ID: 16612649
[TBL] [Abstract][Full Text] [Related]
50. Engineered resistance to camptothecin and antifolates by retroviral coexpression of tyrosyl DNA phosphodiesterase-I and thymidylate synthase.
Nivens MC; Felder T; Galloway AH; Pena MM; Pouliot JJ; Spencer HT
Cancer Chemother Pharmacol; 2004 Feb; 53(2):107-15. PubMed ID: 14605862
[TBL] [Abstract][Full Text] [Related]
51. Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake.
Drori S; Jansen G; Mauritz R; Peters GJ; Assaraf YG
J Biol Chem; 2000 Oct; 275(40):30855-63. PubMed ID: 10899164
[TBL] [Abstract][Full Text] [Related]
52. Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier.
Wang Y; Zhao R; Goldman ID
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6256-64. PubMed ID: 15448015
[TBL] [Abstract][Full Text] [Related]
53. Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: Part II.
Gangjee A; Jain HD; Kurup S
Anticancer Agents Med Chem; 2008 Feb; 8(2):205-31. PubMed ID: 18288923
[TBL] [Abstract][Full Text] [Related]
54. The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates.
Wielinga P; Hooijberg JH; Gunnarsdottir S; Kathmann I; Reid G; Zelcer N; van der Born K; de Haas M; van der Heijden I; Kaspers G; Wijnholds J; Jansen G; Peters G; Borst P
Cancer Res; 2005 May; 65(10):4425-30. PubMed ID: 15899835
[TBL] [Abstract][Full Text] [Related]
55. Cancer research: from folate antagonism to molecular targets.
Bertino JR
Best Pract Res Clin Haematol; 2009 Dec; 22(4):577-82. PubMed ID: 19959110
[TBL] [Abstract][Full Text] [Related]
56. A novel folate transport activity in human mesothelioma cell lines with high affinity and specificity for the new-generation antifolate, pemetrexed.
Wang Y; Zhao R; Chattopadhyay S; Goldman ID
Cancer Res; 2002 Nov; 62(22):6434-7. PubMed ID: 12438230
[TBL] [Abstract][Full Text] [Related]
57. Reduced folate carrier independent internalization of PEGylated pemetrexed: a potential nanomedicinal approach for breast cancer therapy.
Vandana M; Sahoo SK
Mol Pharm; 2012 Oct; 9(10):2828-43. PubMed ID: 22894559
[TBL] [Abstract][Full Text] [Related]
58. The antifolates: evolution, new agents in the clinic, and how targeting delivery via specific membrane transporters is driving the development of a next generation of folate analogs.
Goldman ID; Chattopadhyay S; Zhao R; Moran R
Curr Opin Investig Drugs; 2010 Dec; 11(12):1409-23. PubMed ID: 21154123
[TBL] [Abstract][Full Text] [Related]
59. New approaches to Leishmania chemotherapy: pteridine reductase 1 (PTR1) as a target and modulator of antifolate sensitivity.
Nare B; Luba J; Hardy LW; Beverley S
Parasitology; 1997; 114 Suppl():S101-10. PubMed ID: 9309772
[TBL] [Abstract][Full Text] [Related]
60. Deaza analogs of folic acid as antitumor agents.
Kisliuk RL
Curr Pharm Des; 2003; 9(31):2615-25. PubMed ID: 14529545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
